Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Peptide Receptor Radionuclide Therapy (PRRT) Market Insights

Peptide receptor radionuclide therapy (PRRT) is considered as targeted radionuclide therapy, as it provides radiation to destroy cancer cells via radiolabeled peptides. There are three types of radiations including β−particles (electrons), α particles, and Auger electrons that are used in the peptide receptor radionuclide therapy (PRRT). Among these radiations, β−particles (electrons) are widely used in PRRT, as it has a long range to penetrate in target tissues (0.05–12 mm), and neighboring cells around the targeted cell/tissue. Peptide receptor radionuclide therapy (PRRT) is majorly used in treatment of pancreatic & gastrointestinal tract - neuroendocrine tumor.

Rising incidence of pancreatic neuroendocrine tumor and gastrointestinal tract neuroendocrine tumor is expected to drive the market growth over the forecast period. According to the American Society of Clinical Oncology’s (ASCO) 2019 statistics, around 1,000 people are diagnosed with pancreatic neuroendocrine tumor each year in the U.S. and it accounts for 7% of pancreatic cancer cases. According to the same source, the number of patients diagnosed with pancreatic neuroendocrine tumor has been increasing by around 5% per year in the U.S.

The global peptide receptor radionuclide therapy (PRRT) market was valued at US$ 231.5 million in 2018 and is expected to exhibit a CAGR of 27.3% during the forecast period (2019–2027).

Figure 1. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Share (%), By Disease Indication

Peptide Receptor Radionuclide Therapy (PRRT)  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities, in order to develop novel treatment approach for cancer and regulatory approval for peptide receptor radionuclide therapy are expected to be major factors driving growth of the global peptide receptor radionuclide therapy (PRRT) market over the forecast period

Increasing pipeline studies to develop novel radiopeptide therapy is expected to drive growth of the global peptide receptor radionuclide therapy (PRRT) market over the forecast period. For instance, in May 2018, Merck Sharp & Dome Corp, in collaboration with BTG International Inc., initiated phase II clinical trial on peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases. The study is expected to be completed by November 2020.

Moreover, increasing product approvals by regulatory authority is expected to drive growth of the global peptide receptor radionuclide therapy (PRRT) market. For instance, in June 2019, Advanced Accelerator Applications S.A. (AAA), a Novartis company, received State of Israel Ministry of Health approval for its Lutathera, for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is the first PRRT therapy approved in Israel. Lutathera is a lutetium Lu 177-labeled somatostatin analog peptide.

High cost associated with cancer treatment, which includes diagnosis and therapeutic treatment, is a major factor that is expected to restrain growth of the market

According to the World Health Organization’s 2018 data, the economic impact of cancer is increasing significantly. The total annual economic cost of cancer treatment in 2010 was estimated at US$ 1.16 trillion, globally. Moreover, till 2018, only one PRRT drug was approved in the U.S. and Europe based on peptide receptor radionuclide therapy (PRRT) and used in the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, lack of drugs is another major factor restraining growth of this market. Novartis company’s drug named Lutathera is priced at US$ 47,500 for a full course of treatment, which comprises four infusions (cost for total 4-doses is US$ 190,000). Therefore, such high cost of drugs is expected to restrain growth of this market.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market- Regional Analysis

On the basis of region, the global peptide receptor radionuclide therapy (PRRT) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the market, owing to increasing product approval by regional drug regulatory authorities such as the U.S. FDA and Health Canada, to launch the products in the region. For instance, in January 2018, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, received the U.S. Food and Drug Administration approval for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.

Moreover, Asia Pacific peptide receptor radionuclide therapy (PRRT) market is expected to hold a significant market share during the forecast period, owing to increasing incidence of neuroendocrine tumor and rising adoption of expansion strategies by major manufacturers. For instance, in June 2015, Advance Accelerator Application, a subsidiary of Novartis AG, entered into a distribution agreement for Lutathera with FUJIFILM RI Pharma, Co., LTD. According to the agreement, FUJIFILM will be marketing and distributing Lutathera in the Japan market.

Figure 2: Global Peptide Receptor Radionuclide Therapy (PRRT) Market Share (%), By Region

Peptide Receptor Radionuclide Therapy (PRRT)  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Novartis AG (Advanced Accelerator Applications, S.A.) is the major player operating in the global peptide receptor radionuclide therapy (PRRT) market.

Peptide receptor radionuclide therapy (PRRT) is a molecular therapy (radioisotope therapy) used for the treatment of cancer associated with neuroendocrine tumors (NETs). In PRRT, peptides (cell targeting peptide) combine with a small amount of radioactive material to produce radiopharmaceutical product called radiopeptide. PRRT can be also considered as personalized cancer therapy, as radiopeptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.

Market Dynamics

Rising number of cancer cases is a major factor driving growth of the peptide receptor radionuclide therapy (PRRT) market, globally. According to the American Cancer Society’s 2019 report, in 2018, there were an estimated 17.0 million cases of cancer diagnosed across the world and 9.5 million deaths occurred due to cancer. For instance, according to the World Health Organization’s 2018 report, cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. According to the same source, globally, around 1 in 6 deaths occur due to cancer.

Approvals for PRRT is expected to boost growth of the peptide receptor radionuclide therapy (PRRT) market during the forecast period. For instance, in September 2017, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, received approval from European Medicines Agency (EMA) for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.

Key features of the study:

  • This report provides in-depth analysis of the global peptide receptor radionuclide therapy (PRRT) market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 – 2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global peptide receptor radionuclide therapy (PRRT) market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key player covered as a part of this study include Novartis AG (Advanced Accelerator Applications, S.A.)
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global peptide receptor radionuclide therapy (PRRT) market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global peptide receptor radionuclide therapy (PRRT) industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type:
    • Lutetium (Lu-177)-based
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication:
    • Pancreatic - Neuroendocrine Tumor
    • Gastrointestinal Tract - Neuroendocrine Tumor
    • Others
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Lutetium (Lu-177)-based
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
  • Company Profile
    • Novartis AG (Advanced Accelerator Applications, S.A.)
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies

 “*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Mergers and Acquisitions
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Lutetium (Lu-177)-based
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pancreatic - Neuroendocrine Tumor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Gastrointestinal Tract - Neuroendocrine Tumor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Novartis AG (Advanced Accelerator Applications, S.A.)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 26 figures on “Peptide Receptor Radionuclide Therapy (PRRT) Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner